Poging GOUD - Vrij

China is overplaying its hand with its rare-earth choke-offs

Mint Chennai

|

January 12, 2026

Its export curbs aimed at Japan could prove counterproductive

- DAVID FICKLING

China is overplaying its hand with its rare-earth choke-offs

To a hammer, every problem is a nail. If your most potent means of geopolitical leverage is threatening supplies of high-strength magnets, rare-earth elements will always be the solution.

That's the latest approach Beijing is taking in its dispute with Tokyo. Exports of all items with potential military applications to Japan will be immediately banned, China's ministry of commerce said on Tuesday.

The most obvious victim of this threat will be rare-earth magnets made with the elements neodymium and praseodymium, and increasingly spiced up with rarer samarium, dysprosium and terbium. They're used everywhere from charging cables to the switch-gear in wind turbines to motors powering electric vehicles, missile-guidance systems and aircraft flaps.

There's just one problem: Few countries are better prepared against China threatening their rare-earth supplies than Japan. Thanks to similar threats in 2010, it has spent years diversifying its supply chains and building up stockpiles for precisely this sort of eventuality.

While China produces about 80% of the world's neodymium magnets, Japan manufactures about half the remainder, according to UBS SuMi TRUST Wealth Management—levels far above its own roughly 5% share of global manufacturing.

MEER VERHALEN VAN Mint Chennai

Mint Chennai

Mint Chennai

Lenskart wants artificial intelligence to test your eyes

It expects AI-enabled eye testing to become the default foundational layer of eyecare delivery

time to read

3 mins

January 13, 2026

Mint Chennai

Mint Chennai

More companies to take a hit as labour codes debut

Reworked gratuity and leave encashments spell additional expenses for India Inc

time to read

2 mins

January 13, 2026

Mint Chennai

HC lifts ban on Zydus cancer biosimilar till patent expiry

In a relief for Zydus Lifesciences, a division bench of the Delhi High Court on Monday allowed the drugmaker to sell and market its biosimilar of the anticancer drug nivolumab in India, citing public interest.

time to read

2 mins

January 13, 2026

Mint Chennai

Trump’s investigation of Powell is also a warning to the next Fed chair

The criminal investigation into Federal Reserve Chair Jerome Powell isn’t ultimately about the Fed’s headquarters, or Powell, or even interest rates.

time to read

3 mins

January 13, 2026

Mint Chennai

Mint Chennai

States flag Almont-Kid syrup as tests find contaminants

Syrup found ‘Not of Standard Quality’ with contaminants like toxic ethylene glycol

time to read

1 mins

January 13, 2026

Mint Chennai

Mint Chennai

India at 100: Our choices today will define the next two decades

India's 2047 ambition is not guaranteed but achievable if we address all the potential pitfalls along our development path

time to read

4 mins

January 13, 2026

Mint Chennai

Now, inheritance works without probate—but why it still matters

Heirs can now act on a valid will without court cases, easing delays and unlocking assets in undisputed cases

time to read

6 mins

January 13, 2026

Mint Chennai

Why VCs have a new deep-tech playbook

where fundraising starts to drag,\" said Chand.

time to read

1 min

January 13, 2026

Mint Chennai

TCS, HCLTech deliver Q3 revenue surprise

clearer.

time to read

2 mins

January 13, 2026

Mint Chennai

Mint Chennai

US productivity is rising and it risks warping monetary policy

America's neutral rate ought to be going up but will the Fed listen?

time to read

3 mins

January 13, 2026

Listen

Translate

Share

-
+

Change font size